- Home
- ZVSA vs PHIO Comparison
ZVSA vs PHIO Comparison
Compare ZVSA & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- PHIO
- Stock Information
- Founded
- ZVSA 2014
- PHIO 2011
- Country
- ZVSA United States
- PHIO United States
- Employees
- ZVSA N/A
- PHIO N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- ZVSA Health Care
- PHIO Health Care
- Exchange
- ZVSA Nasdaq
- PHIO Nasdaq
- Market Cap
- ZVSA 2.5M
- PHIO 2.3M
- IPO Year
- ZVSA N/A
- PHIO N/A
- Fundamental
- Price
- ZVSA $1.10
- PHIO $2.61
- Analyst Decision
- ZVSA Strong Buy
- PHIO Strong Buy
- Analyst Count
- ZVSA 1
- PHIO 1
- Target Price
- ZVSA $240.00
- PHIO $36.00
- AVG Volume (30 Days)
- ZVSA 243.8K
- PHIO 30.8K
- Earning Date
- ZVSA 11-14-2024
- PHIO 11-14-2024
- Dividend Yield
- ZVSA N/A
- PHIO N/A
- EPS Growth
- ZVSA N/A
- PHIO N/A
- EPS
- ZVSA N/A
- PHIO N/A
- Revenue
- ZVSA N/A
- PHIO N/A
- Revenue This Year
- ZVSA N/A
- PHIO N/A
- Revenue Next Year
- ZVSA N/A
- PHIO N/A
- P/E Ratio
- ZVSA N/A
- PHIO N/A
- Revenue Growth
- ZVSA N/A
- PHIO N/A
- 52 Week Low
- ZVSA $0.98
- PHIO $2.17
- 52 Week High
- ZVSA $25.00
- PHIO $10.35
- Technical
- Relative Strength Index (RSI)
- ZVSA 41.83
- PHIO 48.74
- Support Level
- ZVSA $0.99
- PHIO $2.58
- Resistance Level
- ZVSA $1.20
- PHIO $2.91
- Average True Range (ATR)
- ZVSA 0.08
- PHIO 0.21
- MACD
- ZVSA 0.04
- PHIO 0.01
- Stochastic Oscillator
- ZVSA 54.55
- PHIO 26.76
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.